Search research articles
Contact Us
Filters
Showing results (321-330 of 342) with videos related to
Page
of 35
Sort By:
Journal of Neuro-Oncology
|
November 3, 2023
Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
Thomas Zeyen, Daniel Paech, Johannes Weller, et al.
Neuro-Oncology
|
March 20, 2024
Insights from a multicenter study on adult H3 K27M-mutated glioma: Surgical resection's limited influence on overall survival, ATRX as molecular prognosticator
Alice Ryba, Zeynep Özdemir, Nitzan Nissimov, et al.
Acta Neuropathologica
|
March 23, 2021
TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma
Christian Thomas, Felix Thierfelder, Malte Träger, et al.
Neuro-Oncology Advances
|
October 26, 2022
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed <i>MGMT</i> promoter methylated <i>IDH</i> wildtype glioblastoma
Lazaros Lazaridis, Elisabeth Bumes, Dorothee Cäcilia Spille, et al.
Cancer Medicine
|
April 22, 2025
Temporal Muscle Thickness as a Prognostic Marker in a Real-Life Cohort of Newly Diagnosed MGMT Promoter Methylated Glioblastoma: A Multicentric Imaging Analysis
Lazaros Lazaridis, Christoph Moenninghoff, Elisabeth Bumes, et al.
Neuro-Oncology
|
October 1, 2024
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomide
Thomas Zeyen, Laura Böhm, Daniel Paech, et al.
Neuro-Oncology
|
November 10, 2017
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma
Niklas Schäfer, Martin Proescholdt, Joachim P Steinbach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2023
Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial
Constantin Roder, Walter Stummer, Jan Coburger, et al.
Neuro-Oncology
|
October 11, 2017
Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07)
Dagmar Beier, Martin Proescholdt, Christiane Reinert, et al.
Acta Neuropathologica
|
July 7, 2018
FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma
Philipp Sievers, Damian Stichel, Daniel Schrimpf, et al.
Page
of 35
Search research articles
Search
Showing results (321-330 of 342) with videos related to
Sort By:
Page
of 35
Journal of Neuro-Oncology
|
November 3, 2023
Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
Thomas Zeyen, Daniel Paech, Johannes Weller, et al.
Neuro-Oncology
|
March 20, 2024
Insights from a multicenter study on adult H3 K27M-mutated glioma: Surgical resection's limited influence on overall survival, ATRX as molecular prognosticator
Alice Ryba, Zeynep Özdemir, Nitzan Nissimov, et al.
Acta Neuropathologica
|
March 23, 2021
TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma
Christian Thomas, Felix Thierfelder, Malte Träger, et al.
Neuro-Oncology Advances
|
October 26, 2022
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed <i>MGMT</i> promoter methylated <i>IDH</i> wildtype glioblastoma
Lazaros Lazaridis, Elisabeth Bumes, Dorothee Cäcilia Spille, et al.
Cancer Medicine
|
April 22, 2025
Temporal Muscle Thickness as a Prognostic Marker in a Real-Life Cohort of Newly Diagnosed MGMT Promoter Methylated Glioblastoma: A Multicentric Imaging Analysis
Lazaros Lazaridis, Christoph Moenninghoff, Elisabeth Bumes, et al.
Neuro-Oncology
|
October 1, 2024
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomide
Thomas Zeyen, Laura Böhm, Daniel Paech, et al.
Neuro-Oncology
|
November 10, 2017
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma
Niklas Schäfer, Martin Proescholdt, Joachim P Steinbach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2023
Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial
Constantin Roder, Walter Stummer, Jan Coburger, et al.
Neuro-Oncology
|
October 11, 2017
Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07)
Dagmar Beier, Martin Proescholdt, Christiane Reinert, et al.
Acta Neuropathologica
|
July 7, 2018
FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma
Philipp Sievers, Damian Stichel, Daniel Schrimpf, et al.
Page
of 35